Nasdaq

Medtronic Receives Approval for U.S. Labeling of the Intellis™ Platform Showing Superior Back Pain Relief When Using DTM™ Spinal Cord Stimulation

Revised Commercial Labeling to Reflect Outcomes of a Randomized Controlled Trial Demonstrating Superiority of DTM™ Spinal Cord Stimulation (SCS) Compared to Conventional SCS for the Treatment of ...
BioWorld

Study shows sustained back pain relief with DTM SCS therapy using Intellis

Medtronic plc reported 12-month data from a large, multicenter, randomized controlled clinical trial affirming the superiority of differential target multiplexed spinal cord stimulation (DTM SCS) in ...
Nasdaq

Medtronic (MDT) Gets FDA Nod for Revised Neuromodulation Labeling

Medtronic plc MDT announced a major regulatory advancement in the fast-growing neuromodulation space. Per the announcement, the company received revised commercial labeling approval from the FDA for ...
JD Supra

Medtronic’s Intellis and Vanta Neurostimulators Receive FDA Approval for DPN

Medtronic announced that its Intellis™ neurostimulator and the Vanta™ neurostimulator have both received approval from the U.S. Food and Drug Administration (FDA) for the treatment of chronic pain ...
BioWorld

Items Tagged with 'Intellis'

Medtronic plc received FDA premarket approval Friday for use of its Intellis rechargeable and Vanta recharge-free neurostimulators in patients with diabetic peripheral neuropathy (DPN), suddenly ...